Q32 Bio Sells ADX-097 to Akebia for Up to $592 Million
Q32 Bio Inc. has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics for up to $592 million. The agreement includes $12 million in upfront and milestone payments, with potential additional payments tied to development, regulatory, and commercial milestones. Q32 Bio plans to use the proceeds to extend its cash runway into 2027 and focus on advancing bempikibart for alopecia areata.
Q32 Bio Inc. has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics. Under the terms of the agreement, Q32 Bio will receive $12 million in upfront and near-term milestone payments, including $7 million at signing, $3 million six months after signing, and $2 million upon the earlier of a milestone achievement or the end of 2026. The deal also includes potential additional payments of up to $592 million tied to development, regulatory, and commercial milestones, as well as tiered royalties on future sales of ADX-097 ranging from low single-digit to mid-teen percentages. Q32 Bio plans to use the proceeds to extend its cash runway into the second half of 2027 and will continue to focus on advancing bempikibart for alopecia areata. The company retains ownership of its remaining tissue-targeted complement inhibitor assets, including ADX-096. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-303115), on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
